Biodexa Pharmaceuticals (BDRX) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Biodexa Pharmaceuticals has successfully appealed a Nasdaq delisting decision, securing an extension to meet the $1.00 minimum bid price requirement. This development provides the company with additional time to stabilize its stock price, crucial for its continued Nasdaq listing. Investors will be watching closely as Biodexa works towards compliance by the end of October 2024.
For further insights into BDRX stock, check out TipRanks’ Stock Analysis page.
